The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market...
-
Upload
roxanne-riley -
Category
Documents
-
view
219 -
download
0
Transcript of The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market...
![Page 1: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/1.jpg)
The Economics of Prescription Drugs
![Page 2: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/2.jpg)
Approach to Analysis
• Structure– Number of firms, market share, historical
antecedents to structure.– Buyer Demand (Pharma Benefits Managers).
• Conduct– Firm behavior (Pricing, Promotion, Innovation)
• Performance– Relative Price Changes, Profits, Innovation
![Page 3: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/3.jpg)
History of Drugs and Regulation
![Page 4: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/4.jpg)
History of Drugs and Regulation
• 1862 USDA Dept of Chemistry• 1906 Pure Food and Drugs Act• 1927 Food, Drug, and Insecticide
Administration• 1930 Food and Drug Administration (FDA)• 1938 Food, Drug, and Cosmetic Act
– Safety
![Page 5: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/5.jpg)
History of Drugs and Regulation
• 1951 Durham-Humphrey Amendment– OTC vs Prescription
• 1962 Kefauver-Harris Amendments– Efficacy and Safety
• 1990 Nutrition Labeling and Education Act
![Page 6: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/6.jpg)
Which is better?
![Page 7: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/7.jpg)
Bio-Pharmaceuticals
• New Chemical Entities (NCEs) – is the basis for Pharma Patents and Regulation.
• Definition: a drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.
• “Moiety”- A type of functional group from Organic Chem
![Page 8: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/8.jpg)
Benzyl acetate - has an ester functional group (in red), an acetyl moiety (circled with green) and a benzyloxy moiety (circled with orange). Other divisions can be made.
![Page 9: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/9.jpg)
![Page 10: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/10.jpg)
![Page 11: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/11.jpg)
Government Regulation
• Regulation by the Food and Drug Administration (FDA)
![Page 12: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/12.jpg)
Stages for a NCE• Discovery• Preclinical animal testing• File application for human testing• Phase I: Test on Healthy Volunteers• Phase II: Test on Large sample of disease pop• Long-term animal studies• Phase III: Test for efficacy and side effects• New drug approval• Average Time (~12 Years)
![Page 13: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/13.jpg)
Liberalization of FDA Process
• Generics• Orphan Drugs• Compassionate Use• User fee act of 1992• Requirement of Prescriptions (Rx)• Liberalization of Rx Req.
![Page 14: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/14.jpg)
Cost Benefit Analysis of Regulation
• Issues of agency, and who suffers the costs and benefits.
Safe Drug Unsafe Drug
Accept Correct Decision Type II Error
Reject Type I Error Correct Decision
![Page 15: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/15.jpg)
Cost Benefit Analysis of Regulation
• Effects of regulation on pharmaceuticals success in world markets
![Page 16: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/16.jpg)
Importance of Pharmaceuticals
![Page 17: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/17.jpg)
Demand for Pharmaceuticals
• Effects of increased insurance coverage for prescription drugs
• Effects of direct marketing
![Page 18: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/18.jpg)
Buyers (Payers)
![Page 19: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/19.jpg)
Trends in Promotional Spending for Prescription Drugs, 1996-2007
$4.9$6.0
$6.6$7.2
$8.5
$10.5
$11.9
$13.5
$15.9
$3.0 $3.4$4.1 $4.3
$5.1 $5.5$6.2
$6.9 $7.3 $6.8 $6.7 $6.3
$0.8 $1.1 $1.3$1.8
$2.5 $2.7 $2.6$3.3
$4.0 $4.2$4.8
$3.7
$0.5 $0.5 $0.4 $0.4 $0.4 $0.5 $0.4 $0.5 $0.4$0.5$0.5$0.5$0
$2
$4
$6
$8
$10
$12
$14
$16
$18
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Retail Value of Sampling Detailing
Direct-To-Consumer Advertising Professional Journal Advertising
Note: NA = Not Available. Numbers may not total due to rounding. Sampling is the value of samples left at sales visits to office-based physicians; the samples are valued at the prices at which they would be sold in retail pharmacies. Sampling data were not available for 2005 and 2006, so Total Spending numbers exclude amounts for Sampling. Detailing is expenses for the sales activities of pharmaceutical company representatives directed to office-based and hospital-based physicians and hospital directors of pharmacies; approximately 85% of detailing is for office-based sales visits. Direct-to-Consumer Advertising is expenses for advertising to consumers through television, magazines and newspapers, radio, and outdoors. Professional Journal Advertising is expenses for advertising appearing in medical journals.
Source: The Kaiser Family Foundation and the Sonderegger Research Center, Prescription Drug Trends, A Chartbook Update, November 2001, Exhibit 17, at http://www.kff.org/insurance/3161-index.cfm, updated by the Kaiser Family Foundation with data from the IMS Health website at http://www.imshealth.com (About Us, Press Room, 2007 Top-Line Industry Data, U.S.).
$27.7 $11.4
$13.9
$16.6 $19.1$12.5
$12.0
$24.2 $21.1$11.0
$9.2Total Spending:
Promotional Spending ($ in billions)
NANANA
$10.4
![Page 20: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/20.jpg)
Gave you the prescription for the
drug you asked about
Recommended a different
prescription
Recommended you make lifestyle/
behavior changes
Recommended any prescription
drug
Recommended an over the counter
drug
Among the 32% who have talked to a doctor as a result of seeing an Rx drug ad: Percent who said the doctor did one or more of the following…
Talking to Doctors as a Result of Prescription Drug Ads, 2008
82%
30%
44%
54%
57%
As a result of seeing an ad for an Rx drug, have you ever talked with a doctor about the specific medicine you saw or heard advertised, or not?
68% 32%
SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)
YesNo
![Page 21: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/21.jpg)
Pricing Issues
• Pricing Differentials between brand name and generic drugs
• Discounts to third party payers
• Pharmacy benefits management firms
• Price differences between countrues
![Page 22: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/22.jpg)
Market Structure• Industry Concentration (RPM – Relevant
Product Market?)
![Page 23: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/23.jpg)
Figure. World Pharmaceutical market
![Page 24: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/24.jpg)
Competition at Product Level
• Within patent competition– Generics after patent expiration– On patent competition from non patent friendly
countries
• Between patent competition– Me Too drugs and the “Gold mine” problem
![Page 25: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/25.jpg)
The Case of ADHD Drugs
![Page 26: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/26.jpg)
Firm Size Effect
• Complicated relationship between – Economies of Scale (Benefits of Large R&D)– Economies of Scope (Spillovers from different
R&D)
![Page 27: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/27.jpg)
Profitability of US Pharma
![Page 28: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/28.jpg)
Profitability of US Pharma
![Page 29: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/29.jpg)
Profitability of Pharmaceutical Manufacturers Compared to Other
Industries, 1995-2006
Note: Percent is the median percent net profit after taxes as a percent of firm revenues for all firms in the industry.
Source: Kaiser Family Foundation and Sonderegger Research Center, Prescription Drug Trends: A Chartbook Update, November 2001, Exhibit 4.11, at http://www.kff.org/insurance/3161-index.cfm, updated with data from Fortune, Fortune 500 Industry Rankings: April 14, 2003, Vol. 147, No. 7, p. F-26; April 5, 2004, Vol. 149, No. 7, p. F-26; April 18, 2005, Vol. 151, No. 8, p. F-28; April 17, 2006, Vol. 153, No. 7, p. F-26; April 30, 2007, Vol. 155, No. 8, p. F-32.
19.6
15.715.814.3
17.018.518.618.618.5
16.117.1
14.4
6.35.95.24.63.13.3
4.55.04.44.95.04.8
0%
5%
10%
15%
20%
25%
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Pharmaceutical Manufacturers
All Fortune 500 Firms
![Page 30: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/30.jpg)
![Page 31: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/31.jpg)
International Trade
• TRIPS (Trade Related Aspects of Intellectual Property Rights 1994)
![Page 32: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/32.jpg)
American Public’s Views About Prescription Drugs
SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)
73%
10%
17%
Do you think Rx drugs developed over the past 20 years have
generally made the lives of people in the U.S…?
Better
Haven’t made much
difference/DK Worse
79%
18%2%
Unreasonable
DK
Reasonable
In general, do you think the price of Rx drugs is
reasonable or unreasonable?
Upside Downside
![Page 33: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/33.jpg)
Serious Problems Paying, Not Filling Prescriptions and Skipping Rx Drug Doses
Because of Cost, 2008
29%
23%
16%
40%
In past two years, have ever NOT filled a prescription because of the
cost
Say it is a serious problem for self/family to pay for Rx drugs you
need
In past two years, have skipped doses or cut pills in half to make Rx last
longer
Percent who say yes to at least one of the above
SOURCE: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008)
![Page 34: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/34.jpg)
16% 17%
43%
9%13%
Total HealthServices and
Supplies
HospitalCare
ProfessionalServices
NursingHome Care
PrescriptionDrugs
NOTE: Does not include spending on SCHIPSOURCE: Kaiser Commission on Medicaid and the Uninsured, based on A Catlin et al, “National Health Spending in 2006: A Year of Change for Prescription Drugs,” Health Affairs 27(1)14-29, January/February 2008. Based on National Health Care Expenditure Data, CMS, Office of the Actuary.
Total National Spending(billions)
$2,106
$648 $660 $125
$217
Medicaid as a share of national health care spending:
Medicaid in the Health System, 2006
![Page 35: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/35.jpg)
Problems Paying for Prescription Drugs, 2008
58%
16%
25%
How much of a problem is it for you or your family to pay for prescription medicines that you need?
A problem, but not serious
Not much of
a problem
A serious problem
41%
Source: USA Today/Kaiser Family Foundation/Harvard School of Public Health: The Public On Prescription Drugs and Pharmaceutical Companies (conducted Jan. 3-23, 2008).
![Page 36: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/36.jpg)
Relative Contributions of Utilization, Types of Prescription Drugs Used, and Price to Rising Prescription Drug Expenditures,
1993-1997 vs. 1997-2002
Source: Kaiser Family Foundation and Sonderegger Research Center analysis using National Health Expenditures data for prescription drugs from the Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, at http://www.cms.gov/statistics/nhe/historical/, Table 2; price data from IMS Health, Pharmaceutical Pricing UPDATE, various years; and utilization data from IMS Health, National Prescription Audit Plus, various years, updated with data from the IMS Health web site at http://www.imshealth.com.
1993-1997 1997-2002
Price (Manufacturer
Price Increases)19% Utilization
(# of Prescriptions Dispensed)
47%Types of
Prescription Drugs Used
34%
Price (Manufacturer
Price Increases)25%
Utilization (# of
Prescriptions Dispensed)
42%
Types of Prescription Drugs Used
34%
![Page 37: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/37.jpg)
Percent of Seniors Who Did Not Fill or Delayed Filling Prescriptions Due to Cost, by Source of Drug Coverage,
2006
NOTES: Did not fill or delayed filling prescriptions due to cost refers to within the past twelve months. VA is Department of Veterans Affairs. Reference group for statistical significance is Part D coverage (*p<0.05).SOURCE: Kaiser/Commonwealth/Tufts-New England Medical Center National Survey of Seniors and Prescription Drugs, 2006.
12% *
8% *
20%
23% *
No Rx Part D Employer VA
(Among Non-Institutionalized Seniors Taking 1 or More Rx)
![Page 38: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/38.jpg)
6 Drugs of the future
![Page 39: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/39.jpg)
Cancer Vaccine
![Page 40: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/40.jpg)
Male Birth Control Pill
![Page 41: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/41.jpg)
Anti-Addiction Pill
![Page 42: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/42.jpg)
Exercise Pill
![Page 43: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/43.jpg)
Anti-Aging Pill
![Page 44: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/44.jpg)
Smart Pill
![Page 45: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/45.jpg)
Pharma Ads
![Page 46: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/46.jpg)
![Page 47: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/47.jpg)
![Page 48: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/48.jpg)
![Page 49: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/49.jpg)
FDA data
![Page 50: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/50.jpg)
FDA data
![Page 51: The Economics of Prescription Drugs. Approach to Analysis Structure – Number of firms, market share, historical antecedents to structure. – Buyer Demand.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649d9c5503460f94a84f7e/html5/thumbnails/51.jpg)
FDA data